๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nagpur
Clinical trial register · India

Clinical Trials in Nagpur

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
Kolkata 54 Delhi 40 Bangalore 39 New Delhi 38 Mumbai 37
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca16 Eli Lilly and Company14 Bristol-Myers Squibb12 Novo Nordisk A/S9 Sanofi6 Clear sponsor filter
Site location
Kolkata54 Delhi40 Bangalore39 New Delhi38 Mumbai37
All 76 locations
Target enrolment
to
16 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
1,500
Bangalore, Indore, Kolkata, Nagpur, Pune, Siliguri, Visakhapatnam
2026-08-21
Recruiting
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
NCT06531798Moderate to Severe COPD
AstraZeneca
Phase 4
150
Dalgate, Drugjan, Hyderabad, Lucknow, Nagpur, New Delhi
2026-01-30
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Bhubaneswar, Chennai, Delhi, Dhanvantari Nagar, Kolkata, Nagpur, Nashik, Surat
2025-12-29
Active, closed
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
NCT06851806Respiratory Syncytial Virus (RSV)
AstraZeneca
Not applicable
21
Hyderabad, Jhฤnsi, Kanpur, Kolkata, Mysore, Nagpur, Pune, Vidyanagar, Hubballi
2025-12-10
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
Bangalore, Delhi, Hyderabad, Kolkata, Mysuru, Nagpur, Nashik, New Delhi
2024-04-29
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
675
Chennai, Dwฤrka, Jaipur, Kolkata, Marg Jaipur, Nagpur, Nashik, New Delhi
2024-04-11
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Bangalore, Calicut, Kanpur, Kolkata, Nagpur, New Delhi, Pune, Vadodara
2023-11-21
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Bengaluru, Delhi, Kolkata, Marg Jaipur, Nagpur, Nashik, Thiruvananthapuram, Vadodara
2023-11-14
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
895
Bengaluru, Hyderabad, Kolkata, Mysuru, Nagpur, Varanasi
2023-10-24
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
AstraZeneca
Phase 3
800
Calicut, Jaipur, Lucknow, Madurai, Mohali, Nagpur, Nashik, New Delhi
2023-09-22
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
AstraZeneca
Phase 3
644
Bangalore, Jaipur, Kolkata, Nagpur, Nashik, New Delhi, Puducherry, Vadodara
2022-05-16
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
AstraZeneca
Phase 3
927
Gurgaon, Howrah, Nagpur, Nashik, New Delhi, Raipur, Rishikesh, Surat
2021-10-25
Active, closed
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
893
Bangalore, Mohali, Mysuru, Nagpur, New Delhi, Vadodara, Varanasi
2021-05-10
Active, closed
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Triple Negative Breast Neoplasms
AstraZeneca
Phase 3
923
Bangalore, Gurgaon, Kolkata, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2019-06-25
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
AstraZeneca
Phase 3
1,246
Gurgaon, Hubli, Kolkata, Mysuru, Nagpur, Nashik, New Delhi, Pune
2018-09-27
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/nagpur

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.